Clinical Study
Orvepitant: A study to Reduce Severe Coughing for People with Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic pulmonary fibrosis (IPF) is a condition that causes scarring of the lungs and severe coughing. Orvepitant is a study drug to reduce chronic coughing for people with IPF. Research is needed to learn the safety and effectiveness of the study drug. Our hope is to provide long-lasting control of chronic cough and a better quality-of-life. The information we gain may aid future patients.
For more information contact:
Chloe Kirkpatrick
chloe.kirkpatrick@hsc.utah.edu
801-581-5811
IRB#: IRB_00152984
| PI: Mary Beth Scholand
| Department: PULMONARY
| Approval Date: 2022-12-14 07:00:00
Specialties: Pulmonary
Who can participate?
Gender: All
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria:
- Ages 40 years and older
- Diagnosis of IPF
- Cough associated with IPF
- If taking pirfenidone or nintedanib, the dose must have been stable for at least 3 months
- Agree to use specific birth control methods if applicable
Exclusion Criteria:
- Recent respiratory tract infection
- Recent acute exacerbation of IPF
- Current smokers or smokers who have quit in the last 6 months
- Specific mental health conditions
- Pregnant
Will I be paid for my time?
Yes